Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kos Will Re-Launch Teveten And Cardizem LA In June Following Biovail Deal

Executive Summary

Kos will re-launch Biovail's three cardiovascular products in June following the addition of 150 Biovail reps to its sales team

You may also be interested in...



Biovail Focus Is Product Development After Divesting Primary Care Sales Reps

Biovail will focus on "recharging its drug development portfolio" as the company moves forward after divesting its primary care sales force, Senior VP-R&D Gregory Szpunar said May 5

Biovail Focus Is Product Development After Divesting Primary Care Sales Reps

Biovail will focus on "recharging its drug development portfolio" as the company moves forward after divesting its primary care sales force, Senior VP-R&D Gregory Szpunar said May 5

Zyprexa Patent Valid: Lilly’s Phase I Olanzapine Trials Were Not “Public Use”

Lilly's conduct of Phase I clinical trials for Zyprexa prior to applying for a composition/use patent did not constitute a prior "public use" that would render the patent invalid, an Indianapolis federal judge ruled April 14

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel